2025-08-19T17:00:31-05:00 2024-12-31 464553740 MANN & ASSOCIATES APC 2535 TRUXTUN ROAD STE 207 SAN DIEGO CA 92106 990EZ 2024-01-01 452210161 THE BIOMEDICAL RESEARCH INSTITUTE OF SOUTHERN CALIFORNIA BIOM 8887235830 4225-H OCEANSIDE BLVD 273 OCEANSIDE CA 92056 SALLY SARAWAR PRESIDENT 8887235830 2025-08-14 1 0 JEANNE M MANN CPA P00229468 6192225900 2024 2025-03-06 01:10:19Z X HTTP://BRI-SC.ORG/ X X 141627 X 21823 119804 141627 17109 5106 106092 362 8202 136871 4756 4854 0 9610 X 60381 53869 0 1772 60381 55641 55527 46031 4854 9610 X THE MISSION OF THIS ORGANIZATION IS TO CONDUCT BASIC RESEARCH TO ADVANCE OUR UNDERSTANDING OF THE FUNDAMENTAL MECHANISMS OF NORMAL BIOLOGICAL PROCESSES AND HOW THOSE DIFFER IN DISEASE STATES. OUR GOAL IS TO IDENTIFY NEW WAYS TO DIAGNOSE, PREVENT OR TREAT HUMAN DISEASE. OUR AREAS OF INTEREST INCLUDE CANCER, DIABETES, OSTEOARTHRITIS, ASTHMA AND OTHER RESPIRATORY DISEASES, TRANSPLANTATION, CHRONIC FATIGUE SYNDROME AND INFECTIOUS DISEASES. VIRAL IMMUNOLOGYTHE OBJECTIVE OF THIS PROGRAM IS TO CONDUCT RESEARCH INTO THE MECHANISMS BY WHICH THE IMMUNE SYSTEM PROTECTS AGAINST VIRAL INFECTIONS. THIS RESEARCH WILL HELP US TO DEVELOP BETTER VACCINES AND THERAPEUTIC AGENTS FOR VIRAL INFECTIONS. THIS PROGRAM INCLUDES PRE-CLINICAL WORK ON A NOVEL UNIVERSAL INFLUENZA VACCINE, THE MECHANISM BY WHICH IT PROTECTS AGAINST MULTIPLE STRAINS OF INFLUENZA AND WHETHER THE VACCINE PROTECTS AGAINST SECONDARY BACTERIAL INFECTIONS OFTEN INCREASE MORTALITY FROM INFLUENZA. WE ARE ALSO INVESTIGATING NOVEL VACCINE ADJUVANTS AND WHY IMMUNE RESPONSES TO CERTAIN VACCINES WANE OVER TIME. DIABETESTHE GOAL OF THIS PROGRAM IS TO IDENTIFY UNIQUE EVENTS AND MOLECULAR PATHWAYS THAT CAN TRIGGER THE AUTOREACTIVE T CELLS TO CAUSE DESTRUCTION OF THE PANCREATIC ISLETS IN TYPE 1 DIABETES. THE ROLE OF EXOSOMES AND NOVEL SELF-ANTIGENS ENCODED BY ENDOGENOUS RETROVIRUSES IS A MAJOR FOCUS OF THIS STUDY. OUR FUNDING FOR THESE PROGRAMS LAPSED IN 2022 AND WE HAD TO SUBLEASE SOME OF OUR OFFICE AND LABORATORY SPACE, TO A COMPANY DEVELOPING NOVEL CANCER DRUGS. WE WERE ABLE TO CONTINUE WORKING ON OUR PROGRAMS USING EXISTING RESOURCES, WHILE ATTEMPTING TO SECURE NEW GRANT FUNDING. WE WERE SUCCESSFUL IN OBTAINING FUNDING; HOWEVER, THE NEW GRANT FUNDING DID NOT START UNTIL MARCH 2023. 0 0 0 PETER DIAS CFO 4.00 0 0 0 CRAIG JACKSON DIRECTOR 0.30 0 0 0 LEMAN YEL DIRECTOR 0.30 0 0 0 MICHAEL GISKE DIRECTOR 0.30 0 0 0 SALLY SARAWAR PRESIDENT AND CEO 16.00 29482 0 0 X 0 0 0 0 0 0 1 30000 0 0 0 0 0 0 0 CA PETER DIAS 4225-H OCEANSIDE BLVD 273 OCEANSIDE CA 92056 8887235830 0 0 0 0 0 0 0 0 0 0 NONE NONE 1 X 352753 138085 2886 178181 21823 693728 352753 138085 2886 178181 21823 693728 693728 69542 130188 119804 319534 1013262 0.68460 0.88880 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED SALLY SARAWAR OFFICER TO PROVIDE A FINANCIAL BUFFER FOR ORGANIZATION TO PREVENT BANK OVERDRAFTS. X 15000 15000 0 1 1 PETER DIAS OFFICER TO PROVIDE A FINANCIAL BUFFER FOR ORGANIZATION TO PREVENT BANK OVERDRAFTS. X 15000 15000 0 1 1 30000 FORM 990-EZ, PART I, LINE 8 - OTHER REVENUE DESCRIPTION: SUBLEASE. AMOUNT: 119,804. FORM 990-EZ, PART I, LINE 14 DESCRIPTION: RENT. AMOUNT: 37,545. DESCRIPTION: UTILITIES. AMOUNT: 23,104. DESCRIPTION: BUILDING MAINTENANCE AND SUPPLIES. AMOUNT: 4,291. DESCRIPTION: WASTE DISPOSAL. AMOUNT: 955. DESCRIPTION: RESEARCH SUPPLIES AND SERVICES. AMOUNT: 142. DESCRIPTION: FRINGE BENEFITS. AMOUNT: 2,538. DESCRIPTION: SALARIES AND OTHER COMPENSATION. AMOUNT: 28,513. DESCRIPTION: OTHER EXPENSES. AMOUNT: 9,004. TOTAL TO FORM 990-EZ, LINE 14: 106,092. FORM 990-EZ, PART I, LINE 16 - OTHER EXPENSES DESCRIPTION: RESEARCH SUPPLIES AND SERVICES. AMOUNT: 4,203. DESCRIPTION: INSURANCE. AMOUNT: 3,262. DESCRIPTION: OFFICE AND COMPUTER SUPPLIES. AMOUNT: 737. TOTAL TO FORM 990-EZ, LINE 16: 8,202. FORM 990-EZ, PART II, LINE 24 - OTHER ASSETS DESCRIPTION: GRANTS RECEIVABLE. BEG. OF YEAR AMOUNT: 0. END OF YEAR AMOUNT: 1,772. FORM 990-EZ, PART II, LINE 26 - OTHER LIABILITIES DESCRIPTION: SECURITY DEPOSIT. BEG. OF YEAR AMOUNT: 4,519. END OF YEAR AMOUNT: 3,096. DESCRIPTION: ACCOUNTS PAYABLE AND ACCRUALS. BEG. OF YEAR AMOUNT: 17,558. END OF YEAR AMOUNT: 7,528. DESCRIPTION: CREDIT CARD PAYABLE. BEG. OF YEAR AMOUNT: 2,914. END OF YEAR AMOUNT: 935. DESCRIPTION: PAYROLL RELATED PAYABLES. BEG. OF YEAR AMOUNT: 0. END OF YEAR AMOUNT: 3,987. DESCRIPTION: DEFERRED REVENUE. BEG. OF YEAR AMOUNT: 485. END OF YEAR AMOUNT: 485. DESCRIPTION: LOANS FROM OFFICERS. BEG. OF YEAR AMOUNT: 30,000. END OF YEAR AMOUNT: 30,000. DESCRIPTION: GRANT RECEIVABLE (NEG). BEG. OF YEAR AMOUNT: 51. END OF YEAR AMOUNT: 0. THE ORGANIZATION DID NOT, DURING THE YEAR, RECEIVE ANY FUNDS, DIRECTLY,OR INDIRECTLY, TO PAY PREMIUMS ON A PERSONAL BENEFIT CONTRACT.THE ORGANIZATION, DID NOT, DURING THE YEAR, PAY ANY PREMIUMS, DIRECTLY,OR INDIRECTLY, ON A PERSONAL BENEFIT CONTRACT.